title: Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report.
abstract: BACKGROUND
  Primary leptomeningeal melanomas are rare tumors that originate in the leptomeninges and are associated with a poor prognosis and no response to radiation and chemotherapy. These tumors rarely metastasize outside the central nervous system. Recombinant interleukin-2-(rIL-2) is a cytokine that activates natural killer cells and lymphokine-activated killer cells, augments their antitumor effects, and recruits and activates cytotoxic T lymphocytes. We have hypothesized that rIL-2 may prolong disease free survival in a patient with primary leptomeningeal melanoma.
  
  
  METHODS
  The patient was treated with intrathecal rIL-2 via lumbar puncture daily for 5 days, the weekly for 5 weeks. To investigate whether rIL-2 induced a favorable clinical response, the following parameters were monitored: survival, neurologic status, cerebrospinal fluid (CSF) analysis, visual fields, and magnetic resonance imaging (MRI) of the lumbosacral spine.
  
  
  RESULTS
  The patient is still alive and disease free 15 months after receiving rIL-2, and his neurologic status remains unchanged. The CFS glucose concentration, undetectable prior to therapy, has become normal. Repeated cytologic examinations of CSF were negative for malignant cells. The visual field examinations have remained unchanged. MRI scans of the lumbosacral spine have shown the development of arachnoiditis, but no recurrence of the mass lesion.
  
  
  CONCLUSIONS
  The tumor response in this patient, as measured by remarkable disease free survival and normalization of the CSF glucose concentration, illustrates the potential benefits of intrathecal rIL-2 in the treatment of patients with this otherwise rapidly fatal disease.
authors.affiliation: Department of Neurology, University of Texas, Southwestern Medical Center at Dallas 75235, USA.
authors.forename: H M
authors.initials: HM
authors.lastname: Fathallah-Shaykh
authors.forename: C
authors.initials: C
authors.lastname: Zimmerman
authors.forename: H
authors.initials: H
authors.lastname: Morgan
authors.forename: E
authors.initials: E
authors.lastname: Rushing
authors.forename: S C
authors.initials: SC
authors.lastname: Schold
authors.forename: D H
authors.initials: DH
authors.lastname: Unwin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006224:Cricetinae; D018572:Disease-Free Survival; D005947:Glucose / Q000134:cerebrospinal fluid; D006801:Humans; D007278:Injections, Spinal; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; D005947:Glucose